Compare NRC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRC | DNA |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 455.8M |
| IPO Year | 1997 | N/A |
| Metric | NRC | DNA |
|---|---|---|
| Price | $17.13 | $5.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 100.0K | ★ 1.2M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 4707.69 | N/A |
| EPS | ★ 50.00 | N/A |
| Revenue | ★ $119,686,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.35 | ★ N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $9.76 | $5.00 |
| 52 Week High | $22.79 | $17.58 |
| Indicator | NRC | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 36.90 |
| Support Level | $14.78 | N/A |
| Resistance Level | $18.29 | $10.05 |
| Average True Range (ATR) | 0.91 | 0.47 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 52.12 | 5.07 |
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.